Mesenchymal Stem Cell– tag –
-
Cell Grand Clinic in Japan Offers Non-Surgical Joint Pain Therapy: Culturing up to 200 Million Autologous Adipose-Derived Stem Cells over 7 Weeks for Direct Injection
Cell Grand Clinic Japan Overview Japan's Cell Grand Clinic announced its offering of a non-surgical joint pain therapy, involving the 7-week culture of autologous stem cells derived from a patient's fat, with up to 200 million cells inje... -
Engineering Approaches to Modify Mesenchymal Stromal Cell (MSC) Immunomodulatory Functions: Advancing Tissue Regeneration and Clinical Application via iPSC-Derived MSCs, Cell Pre-treatment, and EV Therapeutics
PMC International Overview Engineering approaches to modify mesenchymal stromal cell (MSC) immunomodulatory functions are crucial for tissue regeneration and clinical applications. These strategies include cell pre-treatment and genetic ... -
China’s First Approved MSC Therapy, Ruibosheng, Launched at Fraction of Global Price, Receives Conditional Approval for Severe GVHD
BioInformant China Overview China's first approved mesenchymal stem cell (MSC) therapy, Ruibosheng, has been launched at a fraction of global pricing, having received conditional approval from the NMPA on January 2, 2025. Approved for st... -
Catalent Bolsters End-to-End CDMO Services for Autologous & Allogeneic Cell Therapies, Including iPSC Center of Excellence
Catalent USA Overview Catalent is enhancing its end-to-end CDMO manufacturing support and process development services for both autologous and allogeneic cell therapies, covering CAR-T, TCR, TIL, NK cells, and iPSC- and MSC-derived treat... -
Bio-Engine Launches New MSC Culture Media, Achieving 15.1-Hour Doubling Time and 2.8-Fold Exosome Yield Increase
BioEngine Sci-Tech Co, Ltd. China Overview Bio-Engine Sci-Tech Co, Ltd. announced the launch of two new Mesenchymal Stem Cell (MSC) culture medium products: the Omni-Expansion MSC Culture Kit and Exo MSC CD Exosome Expression Kit. Design... -
Taiwan’s ITRI Establishes Highly Stable iPSC-Based MSC and Exosome Manufacturing Platform to Advance Regenerative Medicine
Industrial Technology Research Institute (ITRI) Taiwan Overview Taiwan's Industrial Technology Research Institute (ITRI) has established a highly stable iPSC-based mesenchymal stem cell (MSC) and exosome manufacturing platform. This plat... -
Porton Advanced’s UC-MSC Cell Bank for Exosome Manufacturing Receives FDA Drug Master File (DMF) Acceptance
Morningstar USA Overview Porton Advanced, a CDMO, announced that its umbilical cord-derived mesenchymal stem cell (UC-MSC) cell bank for exosome manufacturing has received Drug Master File (DMF) acceptance from the U.S. FDA. This accepta... -
MSC-Derived Exosomes Emerge as Promising Cell-Free Regenerative Therapies, Driving Active Research in Arthritis, Chronic Wounds, and Inflammatory Diseases
Vertex AI Search USA Overview Mesenchymal Stem Cell (MSC)-derived exosomes are garnering significant attention in regenerative medicine as a cell-free therapeutic alternative, capable of delivering MSCs' potent regenerative and immunomod... -
REPROCELL Submits Application for Manufacturing and Marketing Approval in Japan for Stemchymal® Stem Cell Therapy for Spinocerebellar Ataxia (SCA3 and SCA6)
BioSpace Japan Overview REPROCELL Inc. has submitted an application for manufacturing and marketing approval in Japan for its regenerative medicine product, Stemchymal®, aimed at inhibiting the progression of motor ataxia in patients wit... -
Cellforce One Clinic Tokyo Establishes ‘Cell Processing Governance’ Under Japan’s Regenerative Medicine Law, Offers MSC Therapies for Chronic Pain and Osteoarthritis
Cellforce One Clinic Tokyo Japan Overview Cellforce One Clinic Tokyo, offering integrated regenerative, preventive medicine, and precision imaging, announced the establishment of its 'Cell Processing Governance' in 2026, fully compliant ...
